Aurinia Pharmaceuticals Inc (FRA:IKAP)
€ 8.542 -0.116 (-1.34%) Market Cap: 1.23 Bil Enterprise Value: 978.48 Mil PE Ratio: 0 PB Ratio: 3.30 GF Score: 81/100

Aurinia Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 09:30PM GMT
Release Date Price: €11.91 (+5.40%)
Michael Klem

Good afternoon, everyone. Thank you for joining. My name is Michael Klem. I'm a member of JPMorgan's Healthcare Investment Banking team. It's my pleasure to introduce Peter Greenleaf, the CEO of Aurinia Pharmaceuticals. He's joined here with Joe Miller, the CFO; Neil Solomons, the CMO; and Glenn Schulman, SVP of IR. (Operator Instructions)

Without further ado, I'll turn it over to you, Peter.

Peter S. Greenleaf
Aurinia Pharmaceuticals Inc. - President, CEO & Director

Thanks, Michael, and I want to thank everybody at JPMorgan for having us here at the conference today, and for all investors who sort of lasted through the entire day of activity to join us as we're back and clean up. But we're excited to be here today. Before I get started, obviously, I would just point you towards our website for all most recent filings with the SEC.

As part of our forward-looking statements to start my presentation. While I'm going to just speak freely about who we are, where the business is and where we're going, there is a slide deck, corporate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot